AGIO241220P22500
- 1.60
- 0.000.00%
Agios Pharmaceuticals Newsroom
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $53
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
Agios Pharma (AGIO) Receives a Buy From Piper Sandler
Agios Pharmaceuticals Initiated at Sector Outperform by Scotiabank
Agios Pharmaceuticals Price Target Announced at $51.00/Share by Scotiabank
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
Raymond James Upgrades Agios Pharmaceuticals(AGIO.US) to Buy Rating, Announces Target Price $51
Agios Pharmaceuticals Analyst Ratings
Raymond James Reinstates Outperform on Agios Pharmaceuticals, Announces $51 Price Target
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $56
Leerink Partners Downgrades Agios Pharmaceuticals(AGIO.US) to Hold Rating, Cuts Target Price to $56
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $57
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target